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The objective of this article is to discuss issues
surrounding the conduct of “piggyback evaluations,” in
which health-economic data are collected within an oth-
erwise typical clinical trial.
Methods: We review the methodologic literature on pig-
gyback economic evaluations, as well as selected empiric
studies. We summarize the challenges encountered in the
conduct of these studies, alternative ways of addressing
these challenges, and their future role in pharmacoeco-
nomic research.
Results: Piggyback evaluations have certain advantages
over other types of pharmacoeconomic studies. An eco-
nomic evaluation can beneﬁt from the experimental
design that maximizes the trial’s internal validity, and it is
often more practical to collect economic data alongside a
trial rather than to fund a stand-alone economic study.
However, piggyback evaluations are subject to problems
deriving from the competing nature of clinical versus eco-
nomic study objectives, which can give rise to tension in
such fundamental aspects of study design as the selection
of study subjects and sites; the extent of protocol-
mandated health-care services; and the determination of
sample size, length of follow-up, and the study compara-
tor(s). Many solutions have been put forth in the litera-
ture to address these challenges.
Conclusions: Piggyback evaluations can be an appropri-
ate means to measure the economic impact of medical
interventions, provided that the methodologic challenges
are acknowledged and addressed within the context of
each individual study. As long as a desire for patient-level
data from clinical trials exists, there will be a need for pig-
gyback economic evaluations in the future.
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Economic evaluation has become an important part
of the overall assessment of new medical interven-
tions throughout the world. Evidence of value for
money is increasingly desired along with clinical
safety and efﬁcacy by formulary committees, reim-
bursement authorities, and national health-care sys-
tems. Although there exists a variety of tools and
techniques for conducting economic analyses of
medical interventions, one of the most common
methodologic approaches is to collect data on out-
comes and costs alongside clinical trials.
Such “piggyback” evaluations—so named
because the economic analysis is piggybacked onto
an otherwise typical clinical trial—have been con-
ducted with increasing frequency over the past
two decades. Piggyback economic evaluations have
a number of potential advantages over modeling
studies, retrospective database analyses, and other
types of economic assessments. For one, the eco-
nomic evaluation beneﬁts from randomization,
blinding, and other elements of the experimental
design that reduce bias in the treatment compari-
sons. In addition, a trial represents a convenient
vehicle in which to collect patient-level data on eco-
nomic outcomes, as personnel and processes for
data collection are already in place for the study’s
clinical measures. Finally, from the standpoint of
cost, it is often more feasible to integrate an eco-
nomic component into a clinical trial rather than to
fund a stand-alone economic evaluation at a later
date.
Despite these potential advantages, there are sev-
eral potential pitfalls in the conduct of piggyback
economic evaluations that have made them subject
to criticism from two camps—one claiming that
economic evaluations should only be conducted in
appropriately designed “pragmatic” or “naturalis-
tic” trials, and the other maintaining that trials are




suitable only for the collection of safety and efﬁcacy
data for use in economic models. These concerns
derive from the fact that, once economic measures
are inserted into a trial, it is not uncommon to ﬁnd
that the study’s clinical and economic objectives are
incompatible.
The primary objective of randomized controlled
trials is to demonstrate safety and efﬁcacy. These are
best explored in a highly controlled environment in
which the clinical effects of study agents can be
assessed with minimal bias and confounding. Bias
in the assessment of outcomes and confounding
because of observed and unobserved patient char-
acteristics are minimized by randomizing patients to
treatment and blinding patients and investigators to
treatment assignment. These tactics maximize the
study’s internal validity (i.e., the ability to capture
the “true” treatment effect) for the type of subjects
enrolled in the trial.
In contrast, the objective of an economic evalu-
ation is to examine the outcomes and costs of an
intervention when prescribed by practicing physi-
cians (not blinded investigators) to real patients (not
highly selected study subjects) in actual clinical
practice (not highly controlled experimental condi-
tions). In effect, the same tactics that enhance a clin-
ical trial’s internal validity act to undermine the
economic evaluation, as they create an artiﬁcial
environment that precludes assessment of how well
interventions work and how much they cost when
used in the real world.
The objectives of this article are to review the
issues and problems commonly encountered in the
conduct of piggyback evaluations, to present alter-
native ways of addressing these problems, and to
discuss the future role of piggyback evaluations in
pharmacoeconomic research.
 





One of the most frequently cited methodologic
challenges in the conduct of piggyback economic
evaluations is what is known as “protocol-driven
care.” Protocol-driven care refers to resources
consumed for trial purposes that would not typi-
cally be consumed in standard clinical practice.
Trial protocols prescribe to investigators speciﬁc
guidelines about the frequency and intensity with
which visits, tests, and other health care services
should be provided, inducing bias in economic
outcomes [1,2]. These biases can be summarized
as follows.
Resource consumption in trials deviates from that
in clinical practice. In clinical trials, patients are
typically required to receive more frequent and
intensive physician visits, tests, and treatments than
they would in standard practice, so that clinical out-
comes can be measured and side effects and com-
pliance can be monitored. As a result of this
departure from “real-world” clinical practice, it
may not be possible to extrapolate economic out-
comes from trials to standard practice.
Frequent monitoring in a trial leads to “case
ﬁnding.” Case ﬁnding refers to the discovery of a
previously undetected condition during a protocol-
mandated visit or diagnostic test. It is usually
unknown when or if the condition would have been
discovered in absence of the protocol. Conse-
quently, the appropriateness of including the
resources consumed for the diagnosis and treatment
of the condition in the economic evaluation is
unclear [3].
Patient compliance is actively encouraged and
reinforced in trials.
 
In clinical trials, patient com-
pliance with therapy is actively encouraged during
frequent physician visits to enable measurement of
the treatment effect. In clinical practice, however,
patients would not receive continuous support and
encouragement, and may stop taking medication
because of lack of effectiveness or bothersome side
effects. If compliance is indeed more favorable in a
trial than it would be in clinical practice, economic
outcomes may be biased. For example, economic
costs of treating complications may be underesti-
mated in a trial if trial patients have better outcomes
relative to patients in real-world settings because of
better compliance. On the other hand, drug costs
may be higher in a clinical trial as a result of
enforced compliance with therapy.
There are several possible methods to address the
challenges presented by protocol-driven care. A
commonly applied solution is to net out costs for
protocol-based services from total costs. This is
only possible, however, when the services consumed
for the purposes of the trial can be identiﬁed unam-
biguously [1]. In addition, if protocol-based services
lead to case ﬁnding, it may not be clear if services
for the newly discovered condition should also be
subtracted from total costs, because it would be dif-
ﬁcult to know whether the condition would have
come to the physician’s attention in clinical practice
[4,5]. This strategy may only be a partial solution if
the protocol prevents service use that may have
occurred in its absence. For example, a patient who
experiences a problem during the trial period may




delay going to the doctor if he or she has a protocol
visit scheduled over the next day or so. In this
case, treatment-related resource consumption may
be masked by the study protocol. However, because
case ﬁnding can be assumed to occur to the same
extent in all treatment arms, it is unlikely to affect
incremental costs.
A more direct method of mitigating the effects of
protocol-driven care is to modify the study protocol
so that it is better representative of care provided in
standard practice. Clinical investigators might look
to “naturalistic” or pragmatic trial designs for strat-
egies to address the generalizability of patient man-
agement in clinical trials [6,7]. For instance, in
pragmatic trials focusing on the management of
hypercholesterolemia [8], depression [9], and knee
osteoarthritis [10,11], physicians were free to
manage patients as they saw ﬁt following patient
randomization to treatment, thus making protocol-
driven care a nonissue. Unfortunately, this strategy
will not be viable in the majority of circumstances,
particularly when the clinical trial has been
designed to address important safety and efﬁcacy
measures to gain regulatory approval.
A third alternative constitutes a compromise
approach in that it involves no alterations to the
study protocol with respect to management of
patients in the active treatment and placebo arms,
but entails recruitment of some study subjects into a
“usual care” arm. This usual care arm, which can
be part of the trial or independently set up in par-
allel, contains a group of patients receiving standard
care from study physicians as opposed to care man-
dated by the study protocol. This permits a direct
assessment of the extent to which services provided
within the trial differ from those provided in real-
world clinical practice.
In sum, the problem of protocol-driven care can-
not always be easily addressed in the context of
piggyback evaluations. Subtracting out costs for
protocol-based services is not always a straightfor-
ward task, and may not be a complete solution.
Although a pragmatic trial would allow for more
ﬂexibility in the study’s protocol, oftentimes the
trial design has already been established with a ﬁnal
protocol in place, making it impossible to allow for
a more naturalistic design. In this case, protocol-
based care may best be addressed with the inclusion




Blinding of physicians and patients to treatment
assignment in randomized controlled trials presents
additional challenges to the measurement and gen-
eralizability of economic outcomes in piggyback
evaluations. In double-blind studies, patients and
providers do not have knowledge of the treatment
group to which patients have been assigned, so as to
reduce bias in the assessment of treatment outcomes
[12]. Blinding requires that all study subjects receive
the same tests and services, regardless of treatment
group. In actual clinical practice, however, patients
receiving two different treatment regimens are
unlikely to receive identical services. As an obvious
example, patients who are not receiving active drug
treatment (i.e., the placebo group) would not
require the same tests and services as patients on
active drug therapy [1,2]. Hence, some components
of protocol-driven care can be seen as a conse-
quence of blinding.
As a result of the uniformity of services provided
to patients in both treatment groups, blinding
induces artiﬁcial cost differences between treatment
groups and limits the extent to which real differ-
ences in economic outcomes can be detected. For
example, in a study of oral gold therapy for rheu-
matoid arthritis, toxicity tests were administered to
patients in both the treatment and placebo groups
to maintain blinding [13]. In clinical practice,
patients who do not receive the potentially toxic
therapy would not incur costs for toxicity monitor-
ing; as a result of blinding in the clinical trial, how-
ever, laboratory costs were similar in both groups.
Another consequence of blinding is the inability
to plan for certain economic beneﬁts. To illustrate,
patients receiving a new sedating intervention in
intensive care units (ICU) may have faster recovery
times and consequently earlier discharges from the
ICU. If physicians know which patients have
received the therapy with this added beneﬁt, they
can prepare patients for early discharge; however, in
a blinded study, this is not possible. Finally, blinding
also may affect compliance if the treatment regimen
has multiple doses requiring patients to take addi-
tional placebo pills, as in a double-dummy design.
This was the case in a study of antipsychotic ther-
apy for the treatment of schizophrenia [14].
One way to address the effects of blinding is
to subtract resources consumed for the purposes
of maintaining blinding (e.g., among the placebo
group) from total costs. This strategy was employed
in a study of oral gold therapy for rheumatoid
arthritis [13]. This method may be appropriate pro-
vided the excess resources can be identiﬁed, but
other effects of blinding, such as the inability to
plan for other potential economic beneﬁts (e.g.,
faster recovery times), cannot be accounted for so
easily [5].




A potential alternative to a blinded trial is an
open-label study. While open-label studies reduce
excess service consumption induced by blinding, the
disadvantage is that they are subject to bias result-
ing from knowledge of treatment assignment. In
some cases this may be addressed by blinding only
the assessor of outcomes, although there remains
the risk that patients will reveal the treatment
assignment during a visit. The potential for bias
may also be minimized in an open-label trial with
the use of standardized criteria for determining
clinical response to treatment. This approach was
employed in the TARGET trial of two antibiotic
regimens [15]. The latter approach therefore serves
to reduce bias in service utilization and cost meas-
ures caused by blinding, as well as to reduce the bias
in the efﬁcacy evaluation caused by knowledge of
treatment assignment. Before conducting un-
blinded studies, evidence of beneﬁt from blinded
trials should be established [12].
As with protocol-driven care, there is not always
an easy solution to problems induced by blinding.
Services consumed for the purposes of blinding only
cannot always be identiﬁed unambiguously; in addi-
tion, netting out excess costs may be only a partial
solution. An open-label trial may do well to reduce
the biases resulting from blinding, but this option
may not be feasible if the study design has already
been established, or if the study will be used for reg-
ulatory purposes. Hence, it may not always be pos-
sible to address the problems induced by blinding
and, in certain circumstances this may lead to the
conclusion that the design of the trial is not amena-
ble to the conduct of a piggyback economic evalu-
ation. In such instances, other trials or methods





The methods of patient recruitment for clinical tri-
als may also compromise the generalizability of eco-
nomic outcomes. Although this issue applies to the
clinical outcomes as well, it creates additional prob-
lems for the economic evaluation. Patients who
participate in clinical trials are usually carefully
selected to minimize biological variation and high-
light the treatment effect [2,16]. For example, clin-
ical trial investigators may target patients with
severe cases of the disease under study or exclude
patients with multiple comorbid conditions. How-
ever, study populations generally will not be repre-
sentative of the target population in which the
therapy will be used, making it difﬁcult to extrap-
olate trial results to other settings [5].
One way to gain a better understanding of the
generalizability of trial outcomes is to track out-
comes for a group of patients from outside the trial.
If outcomes are signiﬁcantly different between the
trial population and the community sample, results
from the trial may be of limited use in an economic
evaluation. If an observational study is being con-
ducted in parallel with the piggyback study, results
from the former could be compared with those from
the piggyback study to assess external validity.
When this strategy is not possible, covariate-
adjusted analysis may be used to control for patient
characteristics, so long as there is adequate repre-
sentation of patients with characteristics similar to
those in the target population [17]. For example,
this strategy would be of limited use if the study’s
inclusion and exclusion criteria restricted the study
population to patients under age 65 years, and the
target population included elderly patients. In this
case, prediction from the covariate-adjusted analy-
sis would not provide adequate information about
the target population as a whole. Finally, investiga-
tors may consider reporting the proportion of
patients from the target population excluded from





As is the case for clinical trial populations, sites used
in trials are usually not representative of other prac-
tice settings in which the therapy will be prescribed.
Study sites are typically chosen based on the acces-
sibility of patients and providers, but may differ
from other centers of relevance in terms of practice
patterns, organization, payment incentives, efﬁ-
ciency, prices, and other characteristics that affect
economic outcomes [1,18–20]. For example, teach-
ing and research-based hospitals are known to have
higher costs relative to nonteaching hospitals [16];
these cost differences may be attributable to varying
practice patterns and technological differences or to
differences in the unit costs themselves. Conse-
quently, results from an economic evaluation con-
ducted in a teaching hospital may have limited
generalizability to other types of hospitals. Results
can be further biased if patients who receive care at
trial sites differ from patients receiving care at sites
in standard practice settings. For example, if
patients with relatively severe cases of disease select
institutions that tend to treat more complicated
cases, and these institutions are not employed in the
clinical trial, results from the trial sites may not be
generalizable to centers where severe cases are
treated in practice [20]. While the study’s inclusion




and exclusion criteria may limit the generalizability
of the study population, careful selection of trial
sites may further increase the discrepancy between
trial results and results that would be observed in
standard practice settings.
Multicenter trials could be said to increase gen-
eralizability, because more sites with different prac-
tice patterns are participating. They also increase
the numbers of patients that can be recruited [18].
In the context of a piggyback economic evaluation,
however, if the study centers differ in characteristics
that affect resource use, simple pooling of data from
all centers may not be appropriate. For example,
provider ﬁnancial incentives often affect resource
consumption; if incentives differ across centers,
average costs will not be representative of any of the
centers in the trial [1,21].
Johnston et al. propose using stratiﬁed randomi-
zation of centers by characteristics that are believed
to affect resource use; for example, teaching versus
nonteaching hospitals, or rural versus urban centers
[18]. When this strategy is employed, the distribu-
tion of study center characteristics should mirror
the characteristics of centers in the target setting as
closely as possible. For example, if the distribution
of centers in the setting of interest includes 30%
teaching hospitals and 70% nonteaching hospitals,
centers recruited for the study should have the same
distribution for this characteristic. If centers are
believed to be signiﬁcantly different, resource utili-
zation and prices may be collected for individual
centers, provided the sample size at each center
allows for it [18,21]. Another alternative is to
employ sites that are more representative of centers
in which the target population will be treated. This
strategy was adopted by investigators of the Evalu-
ation of Seroquel on Treatment Outcomes (ESTO)
study, who did not limit their study of schizophrenic




Frequently, in clinical trials, a placebo is used as the
comparator to the study drug, enabling clinical
investigators to net out any “placebo effects” of the
drug and allowing for the maximum treatment effect
to be observed. The goal of economic evaluations,
however, is to inform resource allocation decisions
by comparing a new therapy with the existing or
most commonly accepted standard of care. This
allows for the incremental effects of the product to
be assessed. A placebo comparator limits the utility
of the economic evaluation unless no treatment is the
best standard of care, or the therapy is being eval-
uated for adjunctive use with usual care [7,22,23].
This limitation may be more likely to be encoun-
tered in the United States, where the Food and Drug
Administration often requires placebo-controlled
studies for new drug approvals. In Europe, more
consideration is given to equivalence or noninferi-
ority studies when there is an effective comparator
available [24]. However, an active-controlled trial
does not necessarily guarantee that the comparator
is the appropriate one for the economic analysis.
For piggyback evaluations, the relevant comparator
is the next best alternative, or the one that would be
used in absence of the therapy under study.
Even when investigators are willing to incorpo-
rate an appropriate comparator, in some cases no
clear standard of care can be identiﬁed. For exam-
ple, standard care could change over time or vary by
geographic location. If multiple drugs constitute
standard care, it may not be economically or logis-
tically feasible to incorporate an arm for each such
treatment into the trial. Finally, regardless of
whether or not the initial treatment has a standard
of care, typically there will not be an existing stand-
ard for follow-up or supportive care. For example,
in a trial of antibiotic therapy, patients who were
not cured with ﬁrst-line therapy received varying
follow-up care [15]. When follow-up care is not
standardized across treatment groups, it may be dif-
ﬁcult to make conclusions about the effects of the
initial treatment.
If feasible, a common or mutually agreed upon
standard of care could be employed in the trial, as
demonstrated by investigators of the TARGET
study [15] and the Hylan G-F 20 study [10,11]. It
may also be possible to conduct the trial in a setting
where stepped care is the norm, such as a large
health maintenance organization. Oster and col-
leagues (1995) adopted this approach in the Cho-
lesterol Reduction Intervention Study trial [8].
Finally, investigators may employ a treatment arm
that receives the current standard of care, or alter-
natively, the physician’s “best practice.” Investiga-





The time horizon of clinical trials is usually only
long enough to capture clinically meaningful differ-
ences in relevant treatment outcomes. In contrast,
the ideal length of follow-up for an economic eval-
uation incorporates a time horizon relevant for the
disease outcomes, which may span the patient’s
entire lifetime [21,27]. Short trial durations can
pose several challenges for piggyback economic
evaluations, as follows.




Data collection does not encompass a time horizon
relevant for the disease under study.
 
Clinical tri-
als are typically not long enough to capture out-
comes that occur over the entire course of a
disease. In particular, life-years (or quality-adjusted
life-years [QALYs]) gained from therapy is a pre-
ferred outcome measure in economic evaluations,
because it enables various interventions to be com-
pared in a common metric (i.e., cost per life-year or
QALY gained). Because death is unlikely to be
observed with frequency in trials of short duration,
it may be difﬁcult to estimate life-years saved
directly from trial data. In addition, the time hori-
zon of a clinical trial may not be long enough to
capture differences in economic outcomes when
they are most signiﬁcant [5]. This occurs when
costly outcomes of treatment are endpoint events in
a trial, marking an end to the study and data col-
lection. For instance, typically in cardiovascular
endpoint studies, data collection stops when a
myocardial infarction or stroke occurs, and costs of
care will not be captured [23,28]. Data collection
and management must be revised to capture event-
related costs when economic studies are piggy-
backed onto trials.
 
Data are collected for intermediate health outcomes
only.
 
As a result of the relatively short length of fol-
low-up in trials, data are oftentimes collected on
intermediate outcomes (e.g., blood pressure read-
ings) only, whereas data on ﬁnal outcomes (e.g., life-
years gained from therapy as a consequence of





Patient-level data are censored
when they are incomplete over time. Censoring can
occur either because a patient is lost to follow-up or
because data collection stops at a predetermined
endpoint. An example of the former case is when
data collection ends for a patient who stops taking
medication. In an economic evaluation, it is as
important to track resources consumed by patients
who stop taking medication as it is for patients who
continue on therapy, because discontinuation of
therapy is often associated with adverse clinical out-
comes (e.g., serious adverse events) that have signif-
icant economic implications [2,5]. In the second
case of censored data, a trial may have a ﬁxed end-
point at which data collection stops, making it
impossible to observe long-term outcomes that may
differ between the treatment groups.
The discrepancy between the length of follow-up
in clinical trials and that desired for economic eval-
uations has been addressed in various ways.
 
Extrapolating from ﬁnal endpoints observed in the
trial using modeling techniques.
 
When clinical
outcomes are collected over a shorter time period
than is relevant for the disease, epidemiologic data
and multivariate regression models can be used to
extrapolate trial results beyond the length of follow-
up. Investigators of the GUSTO trial employed both
of these approaches in generating lifetime survival
curves from 1-year survival data [29].
 
Predicting ﬁnal outcomes from intermediate
outcomes using modeling techniques.
 
When data
on intermediate outcomes only are collected in a
trial, epidemiologic data and multivariate regres-
sion models can be used to predict changes in rele-
vant ﬁnal outcomes from changes in intermediate
outcomes. For example, Schulman et al. and Edel-
son et al. used epidemiologic data from the Fram-
ingham Study and regression models to predict
changes in ischemic events from changes in choles-
terol and hypertension parameters, respectively
[30,31].
 
Conducting an open-label extension study.
 
After
data collection on clinical measures has stopped,
investigators can continue to collect economic data
in an open-label extension study. Although open-
label extensions present analytic complexities in
making comparisons between the two treatment
groups, they do provide longer term data on the
patients who were ﬁrst randomized to the drug of
interest.
 
Following withdrawals as long as possible.
 
When
study subjects stop taking medication, it may be
possible to continue data collection for as long as is
relevant for the disease. This approach was demon-
strated in the ESTO study [14].
 
Application of parametric or nonparametric
techniques to analyze censored data.
 
There are
several approaches to addressing the problem of
censored data. Survival analysis methods, such as
the Kaplan-Meier estimator, have been employed
for time-to-event data that are censored [32]. This
method may not be appropriate when patients incur
costs at different rates over time, however, as
patients censored at the same time would have had
different total costs if their data had been available
for the complete follow-up period [33]. Researchers
have developed several alternative methods for this
case, such as nonparametric techniques [34], two-
stage estimators [35], and survival analysis using
weighting techniques [36]. Recently, Lin proposed
several classes of regression models that allow for
time-dependent covariates in the presence of censor-




ing [37]. Where censoring is thought to be substan-
tial, one of these techniques should be applied; at
present there is no clear guidance in the literature as




A well known issue relating to piggyback evalua-
tions, but one that has not yet been adequately
resolved, is the issue of sample size and statistical
power. Sample size calculations for clinical trials
are conducted using the framework of statistical
inference and hypothesis testing with the goal of
estimating the minimum number of patients
required to detect predetermined, clinically impor-
tant treatment differences with a given power and
statistical signiﬁcance level [1]. A problem for eco-
nomic evaluations is that cost comparisons will
generally require larger sample sizes than clinical
comparisons, because of the large variability in
health-care resource use and cost measures. For this
reason, clinical trials will typically be underpow-
ered to detect differences in economic measures
[1,38].
A related problem associated with sample size is
that a trial may be powered for intermediate, rather
than ﬁnal clinical outcomes. For example, trials of
antihypertensive therapy may be powered to detect
meaningful differences in reductions in blood pres-
sure, whereas the ideal outcome for an economic
evaluation may be ischemic events averted or life-
years saved [21,25]. Additional difﬁculties with sta-
tistical signiﬁcance may arise when a rare and costly
event (e.g., a hospitalization) occurs in a trial. In
this case, it may not be clear if the event should be
included in the cost analysis, particularly if it is
unrelated to treatment and affects the signiﬁcance
of the cost difference between groups.
The conduct of trials large enough to detect sig-
niﬁcant differences in economic measures may not
be ﬁnancially feasible; in addition, it may not be
ethical to enroll more patients than is necessary to
demonstrate a clinically meaningful difference [39].
Even if it was ﬁnancially and ethically feasible, it
has been noted that the concept of an “economi-
cally meaningful” difference has not yet been
deﬁned [3,21,39]. The meaning of a quantitatively
important cost difference could depend on the dif-
ferences in clinical effectiveness, the study’s perspec-
tive, and various other factors. Finally, while ideally
a sample size calculation for an economic evalua-
tion would be designed to assess whether the incre-
mental cost per QALY gained is “acceptable,” to
date there is considerable disagreement on what this
threshold should be [21].
In light of these issues, analytic compromises may
be employed. For example, sample size requirements
can be estimated based on an important clinical out-
come that is also believed to be correlated with eco-
nomic outcomes. This approach was adopted by
researchers of the ESTO study, who powered the
study to detect a difference in discontinuation of
therapy [14]. Another approach is to conduct
preliminary or pilot studies to guide sample size
requirements for economic outcomes [40]. Finally,
when a rare but costly event occurs in a trial, a group
of blinded experts could be employed to adjudicate
whether the event is related to the disease or the
therapy, hence relevant for the economic analysis.
As sample size is usually calculated on the pri-
mary clinical efﬁcacy endpoint and not on an eco-
nomic endpoint, inadequate sample size can also be
addressed in the statistical analysis of a piggyback
study. It has been suggested that, even when cost or
effectiveness outcomes are not statistically signiﬁ-
cant, a cost-effectiveness ratio should be presented
along with conﬁdence intervals, however wide, so
that studies that are not adequately powered for the
endpoints will not be misleading [38,39]. There is
also increased interest in the use of Bayesian tech-
niques in cost-effectiveness analyses [41,42]. Here,
results are presented as a cost-effectiveness accept-
ability curve, which provides a graphical depiction
of the probability that the therapy of interest is cost-
effective against various threshold values of willing-
ness to pay for the desired outcome (e.g., life-years
or QALYs gained). Finally, an alternative frame-
work for analyzing cost-effectiveness in the face of
uncertainty has been proposed; this is called the net
beneﬁt statistic[43,44]. The net beneﬁt statistic has
a linear form that is more amenable to examining
uncertainty than the ratio form. In addition, cost-
effectiveness acceptability curves estimated using
the net beneﬁt approach will be identical to those
estimated using an analysis in a cost-effectiveness
plane [44]. Investigators of future piggyback evalu-
ations might consider employing one of these meth-
ods when studies are underpowered for economic
outcomes.
 
Identiﬁcation of Resource Utilization and Cost 
Measures
 
Economic measures collected for piggyback eco-
nomic evaluations should be identiﬁed early in the
design stage of the study [18]. Because in most cases
the identiﬁcation of all resources with the potential
to be consumed over the course of the disease would
be overly burdensome, a subset of the most relevant
resource measures may be identiﬁed.




To identify what resource utilization measures
are important to collect as part of a piggyback eval-
uation, investigators should consider the study’s
perspective (e.g., societal, payer, patient), the trade-
offs between collecting resources consumed for all
conditions versus only those consumed for the dis-
ease under study, and the economic importance of
the measures.
First, the perspective of the study will determine
what measures are relevant for the study. For exam-
ple, a study conducted from a payer’s perspective
need not include costs for patient travel time or lost
productivity, although a study conducted from a
societal perspective should include these costs. Sec-
ond, although the collection of data on resources
consumed for all causes is the most comprehensive
strategy, it is often overly costly and burdensome. In
addition, it may increase variability, making it dif-
ﬁcult to interpret results (e.g., if rare and costly
events occur). When this is the case, data collection
may be limited to resources consumed for the dis-
ease in question. The caveat with the latter
approach is that it may be difﬁcult to determine the
underlying condition for which resources were con-
sumed [25]. Finally, it may be appropriate to limit
economic measures to those of economic impor-
tance. Important economic measures may include
resource consumption that is hypothesized to differ
signiﬁcantly between treatment groups [1], those
that are major cost-generating events (e.g., hospital-
ization) [18], or those that will be consumed by a
large number of patients [45].
It may be difﬁcult to identify important economic
measures a priori; when this is the case, investiga-
tors can use reviews, pretrial studies, pilot studies,
or other previously conducted research that has
measured economic outcomes [18,40]. If such stud-
ies are not available, then expert opinion or inves-
tigator hypotheses can be employed [18,25].
 
Practical Issues in the Conduct of Piggyback 
Economic Evaluations
 
Collection of Resource Utilization Data
 
The most accessible data on patient-level resource
utilization are those that are collected as part of the
clinical trial itself. For example, efﬁcacy measures,
information on adverse events, and various meas-
ures of resource utilization are commonly collected
during the trial as part of the clinical trial protocol.
These data provide a useful resource for the eco-
nomic evaluation, and may reduce the need for
additional data collection. Researchers designing
the economic component of the study should con-
sider how the data collected for clinical purposes
could be utilized for the economic component
before taking on supplemental data collection
procedures.
Although some resource utilization data may be
available among those collected for the purposes of
the clinical trial, usually they need to be supple-
mented with additional data for the economic eval-
uation. Data collected as part of the trial may
include only those relevant to the major payer (e.g.,
managed care organization, government). For
instance, costs for nonmedical resource use (e.g.,
transportation and child care costs) may not be col-
lected as part of the clinical trial, even though they
are treatment-related costs incurred by patients and
their families. Resource utilization data collected
within a trial also may be limited in terms of the
degree of detail, as when the occurrence of hospi-
talization is captured but the individual services
provided during the stay are not.
Supplemental data on patient-level resource uti-
lization can be collected either from medical records
or from the patients themselves, and are typically
recorded on case report forms (CRFs) completed
alongside the trial. If economic measures are iden-
tiﬁed before the commencement of the trial, they
can be incorporated into the CRFs used for clinical
measures, thereby minimizing the number of instru-
ments needed for data collection. With respect to
the source of data for resource utilization, in most
cases consideration of the study’s perspective as well
as the relative advantages and disadvantages of each
method will help guide the decision. These are sum-




The review of medical
records or charts has the advantage of providing
accurate data on patient-level resource use without
additional burden on study subjects. This method
requires informed consent from study subjects
beyond that required for the clinical trial, as well as
procedures and processes to ensure patient conﬁ-
dentiality. In addition, medical records may be
incomplete or unavailable for some study subjects,
and do not contain data necessary to estimate non-
medical resource use and indirect costs (e.g., trans-
portation time, lost productivity) [46]. Finally, if
coding or medical record keeping systems are not
standardized across centers, this method may not be
feasible.
 
Patient diaries or interviews.
 
Information on
resource utilization can also be collected directly
from study subjects. The primary means through
which patients can provide these data are diaries




and interviews. Patient diaries can be completed
after a service has been received or at designated
times; patients can bring diaries with them on pro-
tocol visits or report on their contents during tele-
phone interviews [18]. If patient interviews alone
are used as a means of data collection, they can be
conducted either face-to-face or via telephone. Dia-
ries and interviews permit the collection of patient-
related direct costs, such as travel time, time spent
receiving care, child-care costs, and lost productiv-
ity. However, the potential for various biases exists
when data are collected directly from patients.
Patients may not remember all the services they
received, particularly if the data are collected infre-
quently; frequent assessment may be less subject to
recall bias, but is also more costly and burdensome.
Patient-reported methods are also subject to patient
lack of knowledge regarding the services they
received. Finally, when patients are instructed to
complete diaries on resource use, noncompliance
can hinder data collection and data can be seriously
challenged.
Several researchers have compared medical
records with patient-reported methods—with
mixed results. Although good agreement between
records and patient-reported methods has been
reported for some diseases and procedures, poor
agreement has been reported for others [47,48].
When choosing between the alternatives for data
collection for resource utilization, the potential
biases inherent in each instrument, the potential
burden on patients and investigators, and the cost
of each approach should be considered [18]. If
appropriate, both methods can be employed; for
example, medical records can be used to collect
health-care resource utilization data (e.g., physician
visits) and diaries can be used to collect information
on lost productivity (i.e., work hours missed).
Finally, whenever possible, data collection instru-
ments should be pilot-tested to ensure their validity
and reliability [21].
 
Valuation of Resource Use
 
The assignment of costs to resources consumed dur-
ing the trial is fraught with challenges. Costing can
be performed on a micro or more aggregate level,
and costs can be obtained from sources either inter-
nal or external to the trial.
There are three basic approaches to costing
resource consumption in piggyback evaluations. At
the ﬁnest level is microcosting, using time and
motion methods [49]. Time and motion methods
are typically conducted for cost drivers for which
charges do not vary, or in cases where costs by
severity of disease are desired. For example, if it is
necessary to estimate costs for myocardial infarc-
tions (MIs) of various severity levels, nursing and
physician time and intensity would be measured;
time spent providing care may then be multiplied
by an hourly wage to arrive at the cost of labor
time.
The next level of costing is unit costing, which
applies costs to each resource consumed by the
patient [45,50]. Using the unit costing method, the
cost of an MI could be estimated as the sum of
the costs for the emergency room visit, inpatient
room and board, physician time, tests and proce-
dures performed, and drugs received. Finally, gross
costing employs estimates for an event or diagno-
sis as a whole [40]. To cost an MI event using
gross costing, one might apply a national average
estimate of the total event cost of an MI obtained
from the literature [45].
Microcosting, unit costing, and gross costing
have their relative strengths and weaknesses, as
summarized in Table 2. Ultimately, if one costing
method is deemed appropriate for some resources
consumed in the trial and another method is better
suited for other resources, it may be appropriate to
employ more than one method in a single study
[45]. To illustrate, unit costing may be employed for
health-care services such as drugs, tests, and visits,









• Provide accurate data on resource utilization 
• Minimal burden on patients
• Require patient consent and procedures and processes
for maintaining patient conﬁdentiality
 
• May be incomplete
 
• Lack data on nonmedical resources and indirect costs
• Record keeping/coding may not be standardized across
centers
Patient diaries/interviews • High level of detail possible • Recall bias
• Can provide data on nonmedical resource
use and indirect costs
• Patient lack of  knowledge
• Noncompliance
• May be overly costly and burdensome




ticket” study outcomes, such as MI, stroke, or
another costly medical event.
Microcosting can be conducted using hospital
accounting systems, either internal or external to
the trial. In the United States, unit costing can be
conducted using medical bills of patients in the trial
or an administrative database from outside the trial,
as described below.
Patient bills. The most speciﬁc method of unit cost-
ing is to use the medical bills of the study subjects
enrolled in the trial [45]. Patient bills provide an
accurate representation of patients’ encounters with
the health-care system, and as such can provide pre-
cise data on patient-level charges. This method also
eliminates the need to collect data on resource
utilization separately from unit costs, although
separate data collection allows for better generaliz-
ability. The primary disadvantage of using medical
bills for costing is that in most cases, charges do not
represent actual costs incurred [51]. This discrep-
ancy is typically addressed by adjusting charges
using cost-to-charge ratios, such as those provided
by US Medicare Cost Reports. Caution should be
exercised when average cost-to-charge ratios are
employed (e.g., when study centers cannot be
identiﬁed and it is therefore not possible to
employ institution-speciﬁc ratios), as average
adjustments vary across treatment settings, geo-
graphic areas, and by health-care service type [45].
Administrative databases. Unit costs can also be
acquired from outside the trial using administrative
claims databases. Administrative databases are usu-
ally readily available and have the additional advan-
tage of providing “real-world” data for patients in
clinical practice settings. As with bills, however,
data from claims databases will represent charges,
not costs, and as such may need to be adjusted. In
addition, charges for some services may not be item-
ized separately in a database. For example, routine
tests performed during a physician visit may be
included in the charge for the visit [45]. Finally,
administrative claims data are subject to various
selection biases associated with who is treated with
the intervention in clinical practice [45].
Patient bills and administrative databases are
commonly employed for unit costing in piggyback
evaluations conducted in the United States, but
in general, they are scarcely available in other
countries.
When micro and/or unit costing are deemed to be
overly costly or burdensome for the study, gross
costing can be performed. In the United States, costs
for a disease or study event can be obtained from
the literature or from average Medicare payments
for a hospitalization for the relevant diagnosis
related group (DRG). Costs for outpatient services
(e.g., emergency room visits, ambulatory care) can
be estimated using Ambulatory Payment Classiﬁca-
tions and the relevant Medicare reimbursement
rate. Medicare reimbursement rates based on
resource-based relative value units and regional
Medicare reimbursement rates can be employed to
estimate costs for physician time [50]. In Europe,
fee schedules, hospital costing systems, and results
from DRG studies or the equivalent may be used
[52].
Alternatively, a cost-of-illness study may be
conducted in parallel to the clinical trial. A cost-of-
illness study is an analysis of the total costs of a dis-
ease, usually conducted from a societal perspective.
The conduct of a cost-of-illness study simultane-
ously with a piggyback economic evaluation may be
particularly useful when cost data are scarce for the
condition under study; the study would provide
gross cost estimates that could be applied in a pig-
gyback evaluation until microcost estimates become








 (i.e., time and motion)
• Provides very precise estimates
• Will enable detection of  differences among
various severity levels
• Useful for assessing costs of  different modes
of  drug administration
• Need to account for simultaneous production so that 
provider time is not double-counted
• Not methodologically sound if  true marginal time costs 
to the provider do not equal the sum of  the individual 
costing steps
• May be costly to collect detailed data needed for 
estimation
Unit costing • Provides precise estimates
• Will enable detection of  small cost
differences between groups
• Impractical if  individual cost data are overly 
burdensome to collect
• Allocating costs for overhead is difﬁcult
Gross costing • Estimates may be more readily available and
easier to apply than individual cost estimates
• Sufﬁcient when large differences in costs are
expected
• Subtle cost differences may not be detected
• May not be appropriate if  relevant components (e.g., 
indirect costs) are not included




The costs discussed above primarily refer to
direct health-care costs associated with treatment.
There may be other patient-related costs that are
attributable to obtaining treatment; these costs
should be accounted for in a study conducted from
a patient or societal perspective. These include costs
for traveling to obtain treatment, time spent obtain-
ing care, child-care services, and caregiver time. In
general, the data necessary to estimate these costs
can be obtained through patient diaries. Costs for
lost productivity should also be included. Produc-
tivity losses can be estimated using data on work
hours missed collected from the study subjects and
national average wage rates obtained from the lit-
erature. Wage rates should be obtained for the spe-
ciﬁc population in which the intervention will be
used, although in some cases this could raise equity
concerns. For example, if two interventions are
associated with equal losses in work time but one is
used among men only and the other among women
only, the difference in average wage rates for men
and women may affect the ranking of the cost-effec-
tiveness ratios. In general, however, a targeted wage
rate is desired over a national average wage rate,
so that the appropriate opportunity cost will be
applied [45]. If there is reason to believe that the use
of different wage rates will signiﬁcantly change the
ratios, sensitivity analyses may be employed to
examine the impact of the choice.
 
Conclusions: The Future of Piggyback 
Evaluations
 
When an economic evaluation is piggybacked onto
a clinical trial, it can beneﬁt from the rigorous
experimental design as well as the infrastructure
and processes for prospective data collection.
Despite these potential advantages, piggyback eval-
uations are subject to various problems deriving
from the fact that clinical study objectives are fre-
quently at odds with economic study objectives.
These competing objectives should be given careful
consideration early on in the design stage of a pig-
gyback evaluation. Clinical investigations seek to
assess the “true” treatment effect isolated from any
inﬂuences attributable to patient characteristics,
physician practice patterns, or attributes of the
health-care delivery system. Yet these factors can be
important determinants of economic outcomes and
therefore need to be incorporated explicitly and
accurately in the economic assessment. Whereas the
clinical objective is to remove the inﬂuence of such
factors, the economic objective is to maintain their
inﬂuence.
These issues have made piggyback evaluations
the subject of criticism by both modelers and prag-
matic trial designers. Although in recent years there
has been a renewed interest in developing predictive
models to estimate economic outcomes of new med-
ical technologies, as well as an increase in the imple-
mentation of pragmatic trials, there will continue to
be a need for piggyback evaluations in the future.
This is because many audiences prefer patient-level
data from clinical trials for supportive claims; pig-
gyback trials remain among the most convenient
and timely way to collect patient-level data.
We predict that the future will bring increased
scrutiny regarding what trials are the best candi-
dates for a piggyback economic evaluation. Issues
and challenges will continue to arise in the conduct
of these evaluations. A variety of common-sense
solutions have been put forth by methodologists
and applied researchers in an attempt to address the
issues and challenges discussed in this article; how-
ever, in reviewing this literature, it is clear that there
is no one solution, or set of solutions, that can be
uniformly applied in a “cookie-cutter” fashion to
all trials. Rather, each trial needs to be evaluated in
a considered fashion to seek the most appropriate
set of compromises between its clinical and eco-
nomic components.
In sum, when the various challenges posed by pig-
gyback evaluations are acknowledged and
addressed with rigor, clinical trials can indeed be an
efﬁcient and appropriate means through which to
measure the economic impact of medical interven-
tions. There currently exists no set of blanket
recommendations on how to design and conduct
piggyback economic evaluations, and it is unrealistic
to think that a “one size ﬁts all” approach will ever
come about. But by summarizing the various prob-
lems and pitfalls inherent in piggyback economic
evaluations, along with the associated solutions that
have been identiﬁed, this article sheds light on the
important considerations involved in the collection
of health economic data alongside clinical trials.
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